EXHIBIT 99.1

         INTERPORE CROSS ANNOUNCES COMPLETION OF AMERICAN OSTEOMEDIX
                                  ACQUISITION

IRVINE, CA (July 10, 2001) .... Interpore Cross International (Nasdaq NM: BONZ)
announced today that it has completed its previously announced acquisition of
American Osteomedix Corporation ("AOM"), a privately held developer and
manufacturer of minimally invasive medical devices.  The AOM-CDO System,
introduced in mid-2000, is a controlled delivery system designed to enhance the
efficiency and safety of percutaneous surgery for the placement of materials
into the bony structures of the body.

The transaction has been accounted for as a purchase, and AOM has become a
wholly-owned subsidiary of Interpore Cross.  The purchase price for all of the
outstanding stock and options of AOM was approximately $8 million in cash and
approximately 2.4 million shares of Interpore Cross common stock.  Interpore
Cross has also agreed to pay up to $5 million in additional cash consideration
over the next five years if certain sales goals are met.

According to the Company, the integration of AOM is already underway, and they
are encouraged by the resulting depth and breadth of the combined company's
sales, distribution and operational capabilities.  The company's product suite
of orthopedic devices and materials offers a significant opportunity to create
new markets in a variety of surgical applications.

About Interpore Cross International

Interpore Cross International (www.interpore.com) is a medical device company
                               -----------------
that designs, manufactures and markets spinal implant devices and orthobiologic
products on a worldwide basis.  The spinal products are used to treat
degenerative conditions, deformities and trauma of the spine.  The orthobiologic
products are used for bone and soft tissue repair in orthopedic and other
applications.


INTERPORE CROSS ANNOUNCES COMPLETION OF
AMERICAN OSTEOMEDIX ACQUISITION
Page 2-2-2



This news release contains forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995.  These forward-looking
statements include but are not limited to statements that relate to the
Company's synergies in  sales, distribution and operations,  profitability and
growth, demand for its products or services, growth in the markets it serves or
any other statements that relate to the intent, belief, plans or expectations of
Interpore Cross or its management, or that are not a statement of historical
fact.   Any forward-looking statements in this news release are based on current
expectations and beliefs and are subject to numerous risks and uncertainties
that could cause actual results to differ materially. Other factors that could
cause Interpore Cross' actual results to differ materially are discussed in the
Company's recent filings with the Securities and Exchange Commission.  Interpore
Cross disclaims any obligation to update any forward-looking statements as a
result of developments occurring after the date of this press release.

                                    # # # #
01-12